Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats

Wei Yao, X. Y. Tian, J. Chen, R. B. Setterberg, M. W. Lundy, P. Chmielzwski, C. A. Froman, Webster S S Jee

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cyclic AMP (cAMP) is a continually produced nucleotide inactivated by hydrolysis to 5′AMP via phosphodiesterase (PDE) enzymes. Rolipram is a selective PDE4 inhibitor reported to have anti-inflammatory effects and used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). The current study was designed to determine whether Rolipram could prevent and restore bone loss in ovariectomized (OVX) rats. Six-month-old Sprague Dawley rats underwent either sham-operated or bilateral ovariectomy, and were left untreated for 60 days to develop osteopenia. Then they were treated with vehicle, 6 mg/kg PGE2, 3 μg/kg Alendronate or 0.1-1.0 mg/kg Rolipram for 60 days. At sacrifice, the right tibiae were processed for quantitative bone histomorphometric measurements. The right femurs were measured by dual energy X-ray absorptiometry and the 5th lumbar vertebrae were subjected to micro-computed tomography to access bone mass and architecture changes. Our results indicated that OVX induced negative bone balance in all five bone sites we tested, with bone resorption exceeding bone formation. Rolipram at 0.1-0.6 mg/kg dose levels prevented while at 1 mg/kg restored ovariectomy-induced cancellous and cortical bone loss in the tibia, femur and lumbar vertebra. Dynamic bone histomorphometry suggested that these beneficial effects were achieved by partially maintaining the elevated bone formation at the trabecular bone surface and increasing bone formation at the periosteal bone surface of the cortex. Furthermore, it reduced bone turnover at the trabecular and the endocortical bone surfaces. The prevention of further bone loss effects were comparable to those of an anti-resorption agent (Alendronate) but were not as great as those of an anabolic agent (PGE2). In addition, Rolipram treatment increased body and muscle weights compared to the vehicle-treated OVX rats. In conclusion, our study in an osteopenic rat model suggested that a selective PDE4 inhibitor may be used for the treatment of established osteoporosis.

Original languageEnglish (US)
Pages (from-to)119-130
Number of pages12
JournalJournal of Musculoskeletal Neuronal Interactions
Volume7
Issue number2
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Phosphodiesterase 4 Inhibitors
Rolipram
Bone Resorption
Osteogenesis
Bone and Bones
Alendronate
Lumbar Vertebrae
Ovariectomy
Tibia
Dinoprostone
Femur
Anabolic Agents
Cortical Bone
Cancellous Bone
Bone Remodeling
Metabolic Bone Diseases
Photon Absorptiometry
Phosphoric Diester Hydrolases
Cyclic AMP
Chronic Obstructive Pulmonary Disease

Keywords

  • Bone histomorphometry
  • DEXA
  • Micro-CT
  • Ovariectomy
  • Rat
  • Rolipram

ASJC Scopus subject areas

  • Neuroscience(all)
  • Endocrinology

Cite this

Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. / Yao, Wei; Tian, X. Y.; Chen, J.; Setterberg, R. B.; Lundy, M. W.; Chmielzwski, P.; Froman, C. A.; Jee, Webster S S.

In: Journal of Musculoskeletal Neuronal Interactions, Vol. 7, No. 2, 04.2007, p. 119-130.

Research output: Contribution to journalArticle

@article{50f4642fd0e6413cbf16a2f490453b4d,
title = "Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats",
abstract = "Cyclic AMP (cAMP) is a continually produced nucleotide inactivated by hydrolysis to 5′AMP via phosphodiesterase (PDE) enzymes. Rolipram is a selective PDE4 inhibitor reported to have anti-inflammatory effects and used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). The current study was designed to determine whether Rolipram could prevent and restore bone loss in ovariectomized (OVX) rats. Six-month-old Sprague Dawley rats underwent either sham-operated or bilateral ovariectomy, and were left untreated for 60 days to develop osteopenia. Then they were treated with vehicle, 6 mg/kg PGE2, 3 μg/kg Alendronate or 0.1-1.0 mg/kg Rolipram for 60 days. At sacrifice, the right tibiae were processed for quantitative bone histomorphometric measurements. The right femurs were measured by dual energy X-ray absorptiometry and the 5th lumbar vertebrae were subjected to micro-computed tomography to access bone mass and architecture changes. Our results indicated that OVX induced negative bone balance in all five bone sites we tested, with bone resorption exceeding bone formation. Rolipram at 0.1-0.6 mg/kg dose levels prevented while at 1 mg/kg restored ovariectomy-induced cancellous and cortical bone loss in the tibia, femur and lumbar vertebra. Dynamic bone histomorphometry suggested that these beneficial effects were achieved by partially maintaining the elevated bone formation at the trabecular bone surface and increasing bone formation at the periosteal bone surface of the cortex. Furthermore, it reduced bone turnover at the trabecular and the endocortical bone surfaces. The prevention of further bone loss effects were comparable to those of an anti-resorption agent (Alendronate) but were not as great as those of an anabolic agent (PGE2). In addition, Rolipram treatment increased body and muscle weights compared to the vehicle-treated OVX rats. In conclusion, our study in an osteopenic rat model suggested that a selective PDE4 inhibitor may be used for the treatment of established osteoporosis.",
keywords = "Bone histomorphometry, DEXA, Micro-CT, Ovariectomy, Rat, Rolipram",
author = "Wei Yao and Tian, {X. Y.} and J. Chen and Setterberg, {R. B.} and Lundy, {M. W.} and P. Chmielzwski and Froman, {C. A.} and Jee, {Webster S S}",
year = "2007",
month = "4",
language = "English (US)",
volume = "7",
pages = "119--130",
journal = "Journal of Musculoskeletal Neuronal Interactions",
issn = "1108-7161",
publisher = "International Society of Musculoskeletal and Neuronal Interactions",
number = "2",

}

TY - JOUR

T1 - Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats

AU - Yao, Wei

AU - Tian, X. Y.

AU - Chen, J.

AU - Setterberg, R. B.

AU - Lundy, M. W.

AU - Chmielzwski, P.

AU - Froman, C. A.

AU - Jee, Webster S S

PY - 2007/4

Y1 - 2007/4

N2 - Cyclic AMP (cAMP) is a continually produced nucleotide inactivated by hydrolysis to 5′AMP via phosphodiesterase (PDE) enzymes. Rolipram is a selective PDE4 inhibitor reported to have anti-inflammatory effects and used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). The current study was designed to determine whether Rolipram could prevent and restore bone loss in ovariectomized (OVX) rats. Six-month-old Sprague Dawley rats underwent either sham-operated or bilateral ovariectomy, and were left untreated for 60 days to develop osteopenia. Then they were treated with vehicle, 6 mg/kg PGE2, 3 μg/kg Alendronate or 0.1-1.0 mg/kg Rolipram for 60 days. At sacrifice, the right tibiae were processed for quantitative bone histomorphometric measurements. The right femurs were measured by dual energy X-ray absorptiometry and the 5th lumbar vertebrae were subjected to micro-computed tomography to access bone mass and architecture changes. Our results indicated that OVX induced negative bone balance in all five bone sites we tested, with bone resorption exceeding bone formation. Rolipram at 0.1-0.6 mg/kg dose levels prevented while at 1 mg/kg restored ovariectomy-induced cancellous and cortical bone loss in the tibia, femur and lumbar vertebra. Dynamic bone histomorphometry suggested that these beneficial effects were achieved by partially maintaining the elevated bone formation at the trabecular bone surface and increasing bone formation at the periosteal bone surface of the cortex. Furthermore, it reduced bone turnover at the trabecular and the endocortical bone surfaces. The prevention of further bone loss effects were comparable to those of an anti-resorption agent (Alendronate) but were not as great as those of an anabolic agent (PGE2). In addition, Rolipram treatment increased body and muscle weights compared to the vehicle-treated OVX rats. In conclusion, our study in an osteopenic rat model suggested that a selective PDE4 inhibitor may be used for the treatment of established osteoporosis.

AB - Cyclic AMP (cAMP) is a continually produced nucleotide inactivated by hydrolysis to 5′AMP via phosphodiesterase (PDE) enzymes. Rolipram is a selective PDE4 inhibitor reported to have anti-inflammatory effects and used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). The current study was designed to determine whether Rolipram could prevent and restore bone loss in ovariectomized (OVX) rats. Six-month-old Sprague Dawley rats underwent either sham-operated or bilateral ovariectomy, and were left untreated for 60 days to develop osteopenia. Then they were treated with vehicle, 6 mg/kg PGE2, 3 μg/kg Alendronate or 0.1-1.0 mg/kg Rolipram for 60 days. At sacrifice, the right tibiae were processed for quantitative bone histomorphometric measurements. The right femurs were measured by dual energy X-ray absorptiometry and the 5th lumbar vertebrae were subjected to micro-computed tomography to access bone mass and architecture changes. Our results indicated that OVX induced negative bone balance in all five bone sites we tested, with bone resorption exceeding bone formation. Rolipram at 0.1-0.6 mg/kg dose levels prevented while at 1 mg/kg restored ovariectomy-induced cancellous and cortical bone loss in the tibia, femur and lumbar vertebra. Dynamic bone histomorphometry suggested that these beneficial effects were achieved by partially maintaining the elevated bone formation at the trabecular bone surface and increasing bone formation at the periosteal bone surface of the cortex. Furthermore, it reduced bone turnover at the trabecular and the endocortical bone surfaces. The prevention of further bone loss effects were comparable to those of an anti-resorption agent (Alendronate) but were not as great as those of an anabolic agent (PGE2). In addition, Rolipram treatment increased body and muscle weights compared to the vehicle-treated OVX rats. In conclusion, our study in an osteopenic rat model suggested that a selective PDE4 inhibitor may be used for the treatment of established osteoporosis.

KW - Bone histomorphometry

KW - DEXA

KW - Micro-CT

KW - Ovariectomy

KW - Rat

KW - Rolipram

UR - http://www.scopus.com/inward/record.url?scp=34547868158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547868158&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 119

EP - 130

JO - Journal of Musculoskeletal Neuronal Interactions

JF - Journal of Musculoskeletal Neuronal Interactions

SN - 1108-7161

IS - 2

ER -